FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula (I)
in which R1 is methyl or ethyl and R2 is (C2-3)alkyl substituted with a hydroxy group; or a pharmaceutically acceptable salt thereof. Invention also relates to a compound comprising 1-[4-[5-[5-amino-6-(5-t-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]-1-piperidyl]-3-hydroxypropan-1-one, to combination suitable for use in the treatment of PI3K-α or PI3K-δ, to pharmaceutical composition, to a method for selecting a patient for treating cancer, and to a method of treating a patient suffering from cancer.
EFFECT: new compounds possessing the properties of a kinase inhibitor PI3K-α or PI3K-δ, which can be useful in the treatment of cancer.
17 cl, 13 dwg, 9 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | 2014 |
|
RU2683793C2 |
| TETRAHYDROPYRIDO[3,4-B]INDOLE DERIVATIVES USEFUL IN TREATMENT OF CANCER | 2014 |
|
RU2664109C2 |
| HETEROCYCLIC HIF ACTIVITY MODULATORS FOR TREATING DISEASES | 2013 |
|
RU2698197C2 |
| SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | 2014 |
|
RU2675105C9 |
| NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN | 2022 |
|
RU2834850C2 |
| CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | 2014 |
|
RU2669696C2 |
| AKT ACTIVITY INHIBITORS | 2006 |
|
RU2421454C2 |
| SPIROCYCLIC COMPOUNDS | 2016 |
|
RU2745069C2 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| PYRASOLE[3,4-b]PYRIDINE COMPOUNDS AND THEIR APPLICATION AS PHOSPHODIESTERASE INHIBITORS | 2003 |
|
RU2348633C2 |
